Pfizer said on Wednesday that it will make its full portfolio of patented medicines and vaccines available to low-income nations on a non-profit basis in an effort to close the global healthcare gap, which was highlighted during the Covid-19 epidemic.
The American pharmaceutical company said that it will offer its patented medicines and vaccines to the world’s poorest countries on a non-profit basis.
The initiative, which was announced at the World Economic Forum’s annual meeting in Davos, Switzerland, will make 23 medicines and vaccines available to treat infectious diseases, some cancers, and rare and inflammatory diseases, such as Covid-19, leukemia, breast cancer, pneumonia, and meningitis, according to the company.
The project, which is part of Pfizer’s “An Accord for a Healthier World,” will benefit 1.2 billion people in 45 low-income nations.
Five nations have already signed the agreement: Uganda, Malawi, Senegal, Ghana, and Rwanda. They will strive to identify other impediments to healthcare beyond drug availability, such as supply chain management, policy, and medical education.
Pfizer stated that the lessons learned in these five nations will be “used to assist the roll out for the other forty.”
Pfizer CEO Albert Bourla said that the introduction of vaccinations during the Covid-19 epidemic has proved that “supply is simply the first step to treating patients,” and that the business would engage with health officials to overcome other challenges and address healthcare inequities.
